Abstract
Table 1 lists 66 drugs which exhibit a first-pass effect. A reasonable definition of a first-pass drug is one that exhibits a significant arterial-venous concentration difference at steady-state. Also, after oral administration, and when there is complete absorption of the dose, the area under the blood concentration-time curve is less than the area under the curve when the drug is administered intravenously at the same dose. Figure 1 depicts the meaning of the area (AUC).
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Andrews, J. C., Knutsen, C., Stetson, P. L., Wagner, J.G. and Ensminger, W. D. Hepatic pharmokinetics of 5-bromo-2’-deoxyuridine (BUDR) in a canine model. Clin. Pharmacol. Ther., 41:160 (1987), Abstract II ID-2.
Bass, L. Keiding, S. Winkler, K. and Tygstrup, N. Enzymatic elimination of substrates flowing through the intact liver. J. Theor. Biol., 61:393–409 (1976).
Bass, L., Robinson, P. and Bracken, A. J. Hepatic elimination of flowing substrates: The distribumodel. J. Theor. Biol., 72:161–184 (1978).
Gillette, J. R. Factors affecting drug metabolism. Ann. N.Y. Acad. Sci., 179:43–66 (1971).
Knol, J. A., Stetson, P. L., Wagner, J. and Ensminger, W. D. Hepatic pharmacokinetics of 5-bromo-2’deoxyuridine (BUDR) in the rabbit. Clin. Pharmacol. Ther, 41:171 (1987), Abstract #PPF-3.
Morgan, D. J., Jones, D. B. and Smallwood, R. A. Modeling of substrate elimination by the liver: Has the albumin receptor model superseded the well-stirred model? Hepatology 5:1231–1235 (1985).
Pang, K. S. and Rowland, M. Hepatic clearance of drugs. I. Theoretical consideration of a “well-stirred” model and a “parallel-tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J. Pharmacokin. Biopharm. 5:625–653 (1977). II. Experimental evidence for acceptance of the “well-stirred” model over the “parallel-tube” model using lidocaine in the perfused rat liver in situ preparation. ibid 5:655680 (1977). III. Additional experimental evidence supporting the “well-stirred” model, using metabolite (MEGX) generated from lidocaine under varying hepatic blood flow rates and linear conditions in the perfused rat liver in situ preparation. ibid 5:681-699 (1977).
Pang, K. S. Metabolic first-pass effects. J. Clin. Pharmacol. 26:580–582 (1986).
Roberts, M. S. and Rowland, M. A dispersion model of hepatic elimination. 1. Formulation of the model and bolus considerations. J. Pharmacokin. Biopharm. 14:227–260 (1986).
Robinson, P. J. Aspects of mathematical liver kinetics. The steady state statistical mechanics of hepatic elimination, a thesis. Department of Mathematics, University of Queensland, Brisbane, Australia, 1979.
Rowland, M., Benet, L. Z. and Graham, E.G. Clearance concepts in pharmacokinetics. J. Pharmacokin. Biopharm., 1:123–136 (1973).
Sedman, A. J. and Wagner, J. G. Quantitative pooling of Michaelis-Menten equations in models with parallel metabolite formation paths. J. Pharmacokin. Bio pharm. 2:149–160 (1974).
Silber, B. M., Holford, N. H. G. and Riegelman, S. Dosedependent elimination of propranolol and its major metabolites in humans. J. Pharm. Sci., 72: 725–732 (1983).
Wagner, J. G., Szpunar, G. J. and Ferry, J. J. A nonlinear physiologic pharmaeokinetie model: I. Steady-state. J. Pharmacokin. Biopharm., 13:73–92 (1985a).
Wagner, J. G. Propranolol: Pooled Michaelis-Menten parameters and the effect of input rate on bioavailability. Clin. Pharmacol. Ther., 37:481–487 (1985b).
Wagner, J. G. Comparison of nonlinear pharmaeokinetie parameters estimated from the sinusoidal perfusion and venous equilibration models. Biopharm. Drug Dispos., 6:23–31 (l985c).
Wagner, J. G., Gyves, J. W., Stetson, P. L., WalkerAndrews, S. C., Wollner, I. S., Cochran, M. K. and Ensminger, W.D. Steady-state nonlinearpharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients. Cancer Res., 46:1499–1506 (1986).
Wagner, J. G., Rogge, M. C., Natale, R. B., Albert, K. S. and Szpunar, G. J. Single dose and steady-state pharmacokinetics of adinazolam after oral administration to man. Biopharm. Drug Dispos., accepted January 7, 1987a.
Wagner, J. G., Ling, T., Mrooszczak, E. J., Freeman, D., Wu, A., Huang, B., Massey, I. T. and Ridge, R. Single intravenous dose and steady-state oral pharmacokinetics of nicardipine in healthy subjects. Biopharm. Drug Dispos., accepted April 17, 1987b.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Springer Science+Business Media New York
About this chapter
Cite this chapter
Wagner, J.G. (1988). Modeling First-Pass Metabolism. In: Pecile, A., Rescigno, A. (eds) Pharmacokinetics. NATO ASI Series, vol 145. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-5463-5_7
Download citation
DOI: https://doi.org/10.1007/978-1-4684-5463-5_7
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-5465-9
Online ISBN: 978-1-4684-5463-5
eBook Packages: Springer Book Archive